https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-161
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-1612018-06-26 00:00:002019-02-15 09:00:21Recurrent Glioblastoma Treated with Recombinant Poliovirus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-19 / Oncotarget 2018 Jun;9(47):28702-28716
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-19 / Oncotarget 2018 Jun;9(47):28702-287162018-06-19 00:00:002019-02-15 08:36:18Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e15174)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e15174)2018-06-01 00:00:002018-06-01 00:00:00The effect of Newcastle disease virus on tumor proliferation and cellular immunity.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-22 / Oncol Lett 2018 Jul;16(1):1180-1188
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-22 / Oncol Lett 2018 Jul;16(1):1180-11882018-05-22 00:00:002019-02-15 08:51:37Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-20 / Oncol Res Treat 2018;41(5):292-297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-20 / Oncol Res Treat 2018;41(5):292-2972018-04-20 00:00:002020-12-07 09:37:23Immunotherapy of Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-05 / PLoS ONE 2018;13(4):e0195425
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-05 / PLoS ONE 2018;13(4):e01954252018-04-05 00:00:002019-02-15 09:23:16Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-04 / Acta Trop. 2018 Jul;183:126-133
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-04 / Acta Trop. 2018 Jul;183:126-1332018-04-04 00:00:002019-02-15 09:23:15Newcastle disease virus strain AF2240 as an oncolytic virus: A review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-08 / Exp Ther Med 2018 May;15(5):4522-4530
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-08 / Exp Ther Med 2018 May;15(5):4522-45302018-03-08 00:00:002019-02-15 09:00:23Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-1428
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-14282018-03-05 00:00:002019-02-15 08:36:17PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-250
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-2502018-02-13 00:00:002018-02-13 00:00:00Potentiating prostate cancer immunotherapy with oncolytic viruses
